North America Cancer Photodynamic Therapy Market
市场规模（十亿美元）
CAGR :
% 
USD
1.53 Billion
USD
2.46 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 1.53 Billion |
 Market Size (Forecast Year) |
USD 2.46 Billion |
 CAGR |
% |
| Major Markets Players |
|
北美癌症光動力療法市場細分，依產品類型（光敏劑藥物、光動力療法設備）、癌症適應症（皮膚及皮膚腫瘤、頭頸癌、食道癌、肺癌、膀胱癌、子宮頸癌、攝護腺癌）、治療方式（獨立治療、輔助治療、安寧療護、其他）、手術技術（體外照射、腔內（內視鏡）治療、組織內（體內）治療、其他）、疾病分期（早期癌症、晚期癌症）、患者群（老年人、成人、兒童）、最終用戶（醫院、皮膚科及皮膚癌診所、門診手術中心(ASCS)、學術及研究機構、其他）、分銷管道（直接招標、第三方分銷商、線上、其他）劃分－產業趨勢及至 2032 年的預測
北美癌症光動力療法市場規模
- 2024年北美癌症光動力療法市場規模為15.3億美元，預計到2032年將達到24.6億美元，預測期內複合年增長率為6.2% 。
- 市場成長的主要驅動因素包括癌症發病率上升、醫療保健支出增加以及人們對先進治療方案的認識不斷提高。此外，醫療保健基礎設施的快速改善和專業癌症治療中心的擴張也推動了市場成長。
- 這一增長是由多種因素推動的，例如政府推行早期診斷和創新療法的舉措、龐大的患者群體以及國際和本地公司對光動力療法技術的不斷投資。
北美癌症光動力療法市場分析
- 癌症光動力療法 (PDT) 市場正穩步增長，這主要得益於癌症發病率的上升、人們對非侵入性治療的認識不斷提高，以及光敏劑藥物和雷射技術的進步。北美憑藉其完善的醫療基礎設施和強大的研發投入，在該市場佔據主導地位。
- 在政府扶持、醫療支出成長和老年人口增加的推動下，新興市場正迅速普及光動力療法（PDT）。然而，高昂的治療費用和有限的報銷仍然是限制因素，而聯合療法和標靶光敏劑的持續創新則帶來了巨大的成長機會。
- 預計到2025年，美國將以82.99%的最大市佔率主導北美癌症光動力療法市場。這主要得益於美國先進的醫療基礎設施、創新療法的高普及率、強勁的研發投入、有利的健保政策以及人們對微創療法的認知。此外，市場領導者的存在和完善的監管框架也加速了該地區市場的成長和普及。
- 預計在預測期內，美國將成為北美癌症光動力療法市場成長最快的國家，複合年增長率 (CAGR) 為 6.4%，這主要得益於癌症發病率上升、醫療基礎設施不斷完善、人們對先進療法的認識不斷提高以及政府推行早期診斷的舉措。此外，創新技術的日益普及和可支配收入的增加也推動了對光動力療法的需求。
- 預計到2025年，光敏劑藥物將佔據北美癌症光動力療法市場74.52%的市場份額，其主要驅動因素包括：光敏劑藥物在治療中的核心作用、對癌細胞的高特異性靶向性、新藥獲批數量的增加、聯合療法應用的日益推動，以及持續的研發療效提升和副作用減少。
報告範圍及北美癌症光動力療法市場細分
|
屬性 |
北美絲綢市場關鍵洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家/地區 |
北美洲
|
|
主要市場參與者 |
|
|
市場機遇 |
|
|
加值資料資訊集 |
除了對市場狀況（如市場價值、成長率、細分、地理覆蓋範圍和主要參與者）的洞察之外，Data Bridge Market Research 精心編制的市場報告還包括進出口分析、產能概覽、生產消費分析、價格趨勢分析、氣候變遷情境、供應鏈分析、價值鏈分析、原材料/消耗標準概覽、供應商選擇、PESTLE 分析、五力分析和監管框架。 |
北美癌症光動力療法市場趨勢
“與其他癌症療法的整合”
- 光動力療法（PDT）能夠在局部殺死腫瘤細胞的同時刺激免疫反應，這使其成為多模式癌症治療中極具吸引力的輔助。
- 越來越多的證據表明，光動力療法可以增加腫瘤抗原釋放，調節腫瘤微環境，並增強免疫細胞的浸潤或活化——這些機制可以與免疫檢查點抑制劑、治療性癌症疫苗、化療或放射治療產生協同作用。
- 將光動力療法與全身療法結合，可以將局部控制轉化為持久的全身反應，減少有毒藥物的劑量，並擴大適應症（例如，不可切除或轉移性疾病）。
- 隨著臨床和轉化研究的不斷增多，與其他療法的整合成為拓展光動力療法臨床應用和商業化應用的一條高價值途徑。
北美癌症光動力療法市場動態
司機
“癌症發生率不斷上升”
- 全球癌症發生率的不斷上升是推動光動力療法（PDT）等療法需求成長的主要因素之一。
- 隨著人口增長和老化，以及診斷工具的改進，每年檢測出的癌症病例都在增加。
- 低收入和中等收入國家吸菸、肥胖、久坐不動的生活方式、空氣污染和感染等風險因素發生率較高，也是導致發病率上升的原因之一。
- 隨著越來越多的患者需要有效、微創且經濟的局部治療方式，光動力療法（PDT）變得更具吸引力。
- 癌症負擔日益加重，對醫療系統造成巨大壓力，因此迫切需要能夠改善療效、減少副作用並能更廣泛應用的療法。
克制/挑戰
“光線穿透深度有限”
- 光動力療法的廣泛應用和療效受到的一個重大限制是激活光穿透人體組織的深度有限。
- 由於光敏劑必須被特定波長的光激活，組織對光的吸收和散射會降低光照的深度。
- 可見光光動力療法通常只適用於淺層或易於觸及的腫瘤；對於更深層或更大的腫瘤，治療仍然具有挑戰性。
- 這種限制會導致腫瘤破壞不徹底，需要使用侵入性光療手段（例如光纖探針、內視鏡），增加手術複雜性，並可能導致不良預後或腫瘤復發。
- 在取得突破性進展克服這一難題之前，光動力療法在能夠以非侵入性和有效性治療的癌症範圍方面仍然受到限制。
北美癌症光動力療法市場範圍
市場按產品類型、癌症適應症、治療方式、手術技術、疾病階段、患者人口統計特徵、最終用戶和分銷管道進行細分。
- 依產品類型
根據產品類型，北美癌症光動力療法市場可分為光敏劑藥物和光動力療法設備。預計到2025年，光敏劑藥物將佔據市場主導地位，市佔率高達74.52%，這主要歸功於其在治療效果中的關鍵作用、廣泛的癌症類型適用性以及多樣化的劑型（靜脈注射、局部用藥、口服、膀胱內灌注、腹腔內灌注）。推動這一主導地位的關鍵因素包括癌症發病率的上升、微創療法的日益普及、持續的藥物創新以及監管部門的批准，這些因素共同使得光敏劑藥物成為光動力療法設備的主要收入來源。
由於標靶和微創癌症治療的日益普及，光敏劑藥物成為北美癌症光動力療法市場中成長最快的細分市場，年複合成長率達6.4%。人們對光動力療法的有效性、與傳統療法相比更少的副作用以及具有更高腫瘤選擇性和更深組織穿透性的新一代光敏劑的研發，都推動了市場需求。此外，支持性臨床研究和新型光敏劑的核准也促進了市場擴張。
- 按癌症適應症
根據癌症適應症，北美癌症光動力療法市場可細分為皮膚及皮膚腫瘤、頭頸部腫瘤、食道癌、肺癌、膀胱癌、子宮頸癌和攝護腺癌。預計到2025年，皮膚及皮膚腫瘤細分市場將以51.21%的市場份額佔據主導地位，這主要得益於皮膚癌的高發病率、早期檢測意識的廣泛提高以及光動力療法在實現卓越美容效果方面的有效性。該細分市場受益於光敏劑藥物和光動力療法設備的廣泛應用，尤其是在老年和成年患者群體中，而老年和成年患者群體是該細分市場最大的患者群體。此外，對微創、標靶治療日光性角化病、基底細胞癌和鱗狀細胞癌的需求不斷增長，以及主要地區有利的醫療保險政策，進一步鞏固了其在其他癌症適應症領域的市場領先地位。
在北美癌症光動力療法市場中，皮膚及皮膚腫瘤領域成長最快，複合年增長率達6.8%。這主要得益於皮膚癌發病率的上升、人們對早期診斷意識的增強以及對微創、副作用更少的治療方式的偏好。光動力療法具有標靶作用、恢復快、美觀效果好等優點，因此在皮膚腫瘤治療領域備受青睞。此外，光敏劑和光傳輸系統的技術進步也推動了該領域光動力療法的應用。
- 按治療方式
根據治療方式，北美癌症光動力療法市場可分為獨立治療、輔助治療、安寧療護和其他。預計到2025年，獨立治療將佔據市場主導地位，市佔率達39.97%，主要歸功於其作為局部癌症（包括皮膚癌、食道癌和肺癌）一線治療的有效性。推動這一主導地位的關鍵因素包括高療效、微創性、優異的美容效果以及臨床上對標靶治療日益增長的偏好。從區域來看，北美和歐洲由於擁有先進的醫療基礎設施、完善的報銷機制和較高的患者認知度，在獨立光動力療法的應用方面處於領先地位；而亞太新興市場則在癌症發病率上升、醫院網絡不斷擴展以及現代腫瘤治療手段日益普及的推動下，其應用也在不斷增長。這些區域動態，加上人們對光動力療法益處的認識和教育水平不斷提高，進一步鞏固了獨立治療在全球的主導地位。
在北美癌症光動力療法市場中，獨立療法因其簡單、經濟高效且副作用低於聯合療法，成為成長最快的細分市場，年複合成長率達6.8%。它無需額外藥物或乾預即可進行標靶腫瘤治療，從而提高了患者的依從性。門診應用的日益普及、人們對微創治療認識的提高以及光敏劑和光傳輸系統的進步，都進一步推動了該細分市場的快速成長。
- 透過程式技術
根據治療技術，北美癌症光動力療法市場可分為體外照射、腔內（內視鏡）照射、組織間（體內）照射和其他方式。預計到2025年，體外照射療法將佔據市場主導地位，市佔率高達68.32%，主要得益於其非侵入性、易用性和對表淺腫瘤的有效性。北美和歐洲地區先進的醫療基礎設施和報銷政策推動了該療法的廣泛應用，而亞太地區癌症發病率的上升和公眾意識的提高也帶動了該療法需求的增長，這些因素共同促成了體外照射療法的市場領先地位。
在北美癌症光動力療法市場中，腔內（內視鏡）輸送細分市場成長最快，年複合成長率達 6.2%，因為它能夠以微創的方式將光和光敏劑靶向輸送到空腔器官腫瘤，減少全身暴露和副作用，允許重複治療，改善食道癌、支氣管癌和膀胱癌的腫瘤可及性，並縮短恢復時間。
- 按疾病階段
根據疾病分期，北美癌症光動力療法市場分為早期癌症和晚期癌症兩大類。預計到2025年，早期癌症細分市場將佔據81.12%的市場份額，這主要得益於光動力療法能夠有效靶向局部腫瘤，最大限度地減少對健康組織的損傷，並提供更佳的美容效果。該細分市場受益於患者對光動力療法的高度認知、對微創治療的偏好以及在北美和歐洲的廣泛應用，同時，亞太地區癌症診斷率的上升和腫瘤治療基礎設施的不斷完善也進一步鞏固了其市場領先地位。
在北美癌症光動力療法市場中，早期癌症是成長最快的細分市場，年複合成長率達6.3%。這主要得益於微創治療的日益普及、人們對早期檢測意識的提高以及光動力療法（PDT）帶來的患者療效改善。早期癌症對標靶治療的反應較佳，因此療效較高，副作用較少。此外，政府的支持性政策以及光敏劑和光傳輸系統的進步也推動了該細分市場更快的滲透。
- 按患者人口統計特徵
根據患者人口統計數據，北美癌症光動力療法市場可分為老年人、成人和兒童三大群體。預計到2025年，老年人群將佔據市場主導地位，市場份額高達66.15%，這主要歸因於老年人癌症發病率較高、皮膚癌和皮膚皮膚癌的易感性增加，以及老年人更傾向於微創、標靶治療。北美和歐洲地區對光動力療法的接受度很高，這得益於先進的醫療基礎設施、較高的公眾意識以及不斷增長的老齡人口。
由於老年族群癌症發生率較高，老年患者族群成為北美癌症光動力療法市場成長最快的細分市場，年複合成長率達6.5%。老化會削弱免疫系統，增加各種癌症的風險，從而推動了對高效、微創療法（如光動力療法）的需求。此外，光動力療法副作用更少，恢復更快，因此更適合可能無法耐受侵入性療法的老年患者，這也促進了該族群市場的成長。
- 最終用戶
根據最終用戶劃分，北美癌症光動力療法市場可細分為醫院、皮膚科及皮膚癌診所、門診手術中心 (ASCS)、學術及研究機構以及其他機構。預計到 2025 年，醫院將佔據市場主導地位，市場份額達 40.10%，這主要得益於其完善的基礎設施、專業的腫瘤科室以及提供綜合性光動力療法 (PDT) 治療的能力。公立和私立醫院，尤其是北美和歐洲的一級和二級醫院，由於其先進的醫療保健系統和報銷支持，引領光動力療法的應用。亞太地區醫院網路的不斷擴展和腫瘤服務的日益普及，進一步鞏固了醫院作為全球癌症光動力療法主要最終用戶的主導地位。
在北美癌症光動力療法市場中，醫院是成長最快的細分市場，年複合成長率達7.0%，這主要得益於先進癌症療法的普及、病患數量增加以及專科腫瘤科室的普及。醫院提供包括診斷、治療和術後護理在內的綜合性光動力療法服務，因此比獨立診所更具優勢。此外，公眾意識的提高、政府的扶持政策以及保險覆蓋範圍的擴大也進一步推動了醫院光動力療法的應用。
- 透過分銷管道
根據分銷管道，北美癌症光動力療法市場可分為直接招標、第三方分銷商、線上銷售和其他管道。預計到2025年，直接招標管道將佔據市場主導地位，市場份額達49.75%，這主要得益於醫院、政府醫療保健項目和大型腫瘤中心的批量採購，從而確保了光敏劑和光動力療法設備的成本效益和穩定供應。北美和歐洲市場對該療法的強勁需求，得益於完善的醫院採購體系和公共衛生招標，以及不斷增長的機構需求。
在北美癌症光動力療法市場中，直接招標細分市場成長最快，年複合成長率達6.5%，這主要得益於政府和醫院越來越多地透過直接合約採購先進的光動力療法設備。這種方式確保了成本效益、採購速度和大型癌症治療計畫的可靠供應。此外，不斷增長的公共醫療支出、政府對癌症治療的扶持政策以及對集中採購的偏好，都推動了直接招標方式相對於分銷商或線上管道的普及。
北美癌症光動力療法市場區域分析
- 預計到2025年，美國將以82.99%的最大市佔率主導北美癌症光動力療法市場。這主要得益於美國先進的醫療基礎設施、創新療法的高普及率、強勁的研發投入、有利的健保政策以及人們對微創療法的認知。此外，市場領導者的存在和完善的監管框架也加速了該地區市場的成長和普及。
- 預計在預測期內，美國將成為北美癌症光動力療法市場成長最快的國家，複合年增長率 (CAGR) 為 6.4%，這主要得益於癌症發生率上升、醫療基礎設施不斷完善、人們對先進療法的認知度不斷提高以及政府推行早期診斷的舉措。此外，創新技術的日益普及和可支配收入的增加也推動了對光動力療法的需求。
- 此外，領先的市場參與者和支持性的監管框架的存在，加速了該地區的市場成長和普及率。
美國北美癌症光動力療法市場洞察
2024年，美國北美癌症光動力療法市場佔據北美最大市場份額，這得益於先進的醫療基礎設施、創新療法的高普及率以及強勁的研發投入。主要光動力療法設備製造商的入駐、有利的醫保報銷政策以及癌症發病率的上升推動了市場收入的成長。此外，提高公眾意識的宣傳活動和早期診斷措施也促進了治療的普及。技術進步、有利的監管環境以及患者較高的消費能力，共同使美國成為最大的收入貢獻者。
加拿大北美癌症光動力療法市場洞察
2024年，加拿大北美癌症光動力療法市場在北美地區穩步增長，這主要得益於癌症發病率的上升、政府醫療保健資金的支持以及光動力療法設備和光敏劑監管審批的加快。專科腫瘤中心對光動力療法的接受度不斷提高、醫生認知度的提升、越來越多的臨床證據證實其對錶面和局限性腫瘤的療效，以及醫院與生物技術公司之間的合作，都推動了光動力療法的普及。病患對微創治療的偏好以及健保報銷政策的改善，進一步促進了加拿大各省光動力療法市場的擴張。
市場上的主要市場領導者包括：
- 諾華製藥股份公司（瑞士）
- 高德美公司（瑞士）
- 博士倫健康公司（加拿大）
- Photocure ASA（挪威）
- ADVANZ PHARMA Corp.（英國）
- 太陽製藥工業有限公司（印度）
- Biofrontera AG（德國）
- LUMIBIRD SA（法國）
- LUZITIN SA（葡萄牙）
- Lumeda公司（瑞典）
- ImPact Biotech（以色列）
- biolitec Holding GmbH & Co KG（德國）
- Modulight公司（芬蘭）
- THERALASE TECHNOLOGIES INC.（加拿大）
北美癌症光動力療法市場最新進展
- 2023年2月，高德美（Galderma）與德國醫療工程公司（GME）的合作標誌著皮膚病學和光動力療法（PDT）市場的一項策略性發展。透過將高德美領先的用於治療癌前病變和非黑色素瘤皮膚癌的光敏劑Metvix與GME的MultiLite設備相結合，此次合作增強了高德美的綜合治療方案，並擴展了其提供傳統紅光光動力療法（C-PDT）和更利於患者的人工日光光動力療法（ADL-PDT）的能力。
- 2025 年，麥克森完成了對 Core Ventures（社區腫瘤振興企業創投公司）的收購，以約 24.9 億美元的價格收購了約 70% 的控股權，以透過佛羅裡達癌症專家和研究所加強其以社區為基礎的腫瘤護理。
- 2025 年，Biofrontera AG 將與 Ameluz 和 RhodoLED 相關的所有美國資產轉讓給了 Biofrontera Inc.，獲得了 10% 的股權以及美國 Ameluz 銷售額 12-15% 的特許權使用費。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PRODUCTION CONSUMPTION ANALYSIS
4.3.1 INTRODUCTION
4.3.2 PRODUCTION SIDE ANALYSIS
4.3.2.1 PHOTOSENSITIZER MANUFACTURING
4.3.2.2 DEVICE MANUFACTURING
4.3.2.3 RESEARCH AND INNOVATION
4.3.3 CONSUMPTION SIDE ANALYSIS
4.3.3.1 CLINICAL APPLICATION
4.3.3.2 TREATMENT VOLUMES AND TRENDS
4.3.3.3 DOSAGE AND PROTOCOLS
4.3.4 PRODUCTION–CONSUMPTION DYNAMICS
4.3.4.1 SUPPLY CONSTRAINTS
4.3.4.2 REGIONAL OVERVIEW
4.3.4.3 FUTURE OUTLOOK
4.3.5 CONCLUSION
4.4 COST ANALYSIS BREAKDOWN
4.4.1 INTRODUCTION
4.4.2 DIRECT MEDICAL COSTS
4.4.2.1 COST OF PHOTOSENSITIZERS
4.4.2.2 LIGHT DELIVERY SYSTEMS
4.4.2.3 HEALTHCARE FACILITY CHARGES
4.4.3 INDIRECT COSTS
4.4.3.1 PATIENT-RELATED EXPENSES
4.4.3.2 POST-TREATMENT MONITORING
4.4.4 COMPARATIVE COST-EFFECTIVENESS
4.4.5 REIMBURSEMENT AND INSURANCE IMPACT
4.4.6 REGIONAL COST VARIATIONS
4.4.7 FUTURE COST TRENDS AND REDUCTION STRATEGIES
4.4.7.1 TECHNOLOGICAL ADVANCEMENTS
4.4.7.2 HEALTHCARE EFFICIENCY INITIATIVES
4.4.8 CONCLUSION
4.5 TECHNOLOGICAL ADVANCEMENTS
4.5.1 INTRODUCTION
4.5.2 NEXT-GENERATION PHOTOSENSITIZERS
4.5.3 ADVANCEMENTS IN LIGHT DELIVERY SYSTEMS
4.5.4 NANOTECHNOLOGY-ENABLED DELIVERY
4.5.5 COMBINATION THERAPIES AND IMMUNOMODULATION
4.5.6 DIGITAL INTEGRATION AND TREATMENT PLANNING
4.5.7 RECENT TRENDS AND OUTLOOK
4.5.8 CONCLUSION
4.6 VALUE CHAIN ANALYSIS
4.6.1 INTRODUCTION
4.6.2 RESEARCH & DEVELOPMENT
4.6.2.1 DISCOVERY OF PHOTOSENSITIZERS
4.6.2.2 DEVELOPMENT OF LIGHT DELIVERY SYSTEMS
4.6.2.3 CLINICAL TRIALS AND REGULATORY APPROVALS
4.6.3 MANUFACTURING
4.6.3.1 PRODUCTION OF PHOTOSENSITIZERS
4.6.3.2 FABRICATION OF LIGHT DELIVERY DEVICES
4.6.4 DISTRIBUTION & LOGISTICS
4.6.4.1 SUPPLY CHAIN MANAGEMENT
4.6.4.2 INTERNATIONAL TRADE AND MARKET ACCESS
4.6.5 CLINICAL APPLICATION
4.6.5.1 INTEGRATION INTO TREATMENT PROTOCOLS
4.6.5.2 TRAINING AND EDUCATION
4.6.6 POST-TREATMENT MONITORING & SUPPORT
4.6.6.1 FOLLOW-UP CARE
4.6.6.2 PATIENT SUPPORT SERVICES
4.6.7 TECHNOLOGICAL ADVANCEMENTS INFLUENCING THE PDT VALUE CHAIN
4.6.7.1 NANOTECHNOLOGY IN PDT
4.6.7.2 ARTIFICIAL INTELLIGENCE AND IMAGING
4.6.7.3 PERSONALIZED MEDICINE
4.6.8 CONCLUSION
4.7 VENDOR SELECTION CRITERIA
4.7.1 INTRODUCTION
4.7.2 CORE SELECTION CRITERIA
4.7.2.1 REGULATORY COMPLIANCE
4.7.2.2 CLINICAL EVIDENCE AND RESEARCH SUPPORT
4.7.2.3 TECHNICAL PERFORMANCE AND DEVICE COMPATIBILITY
4.7.2.4 QUALITY MANAGEMENT AND MANUFACTURING STANDARDS
4.7.2.5 SERVICE, TRAINING, AND AFTER-SALES SUPPORT
4.7.2.6 SUPPLY CHAIN RELIABILITY
4.7.3 RECENT TRENDS IN VENDOR SELECTION
4.7.4 RISK FACTORS AND VULNERABILITIES
4.7.5 KEY PERFORMANCE INDICATORS
4.7.6 STRATEGIC RECOMMENDATIONS
4.7.7 CONCLUSION
4.8 PATENT ANALYSIS
4.8.1 PATENT QUALITY AND STRENGTH
4.8.2 PATENT FAMILIES
4.8.3 LICENSING AND COLLABORATIONS
4.8.4 REGIONAL PATENT LANDSCAPE
4.8.5 IP STRATEGY AND MANAGEMENT
4.9 SUPPLY CHAIN ANALYSIS
4.9.1 OVERVIEW
4.9.2 LOGISTIC COST SCENARIO
4.9.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS
4.9.4 CONCLUSION
4.1 INDUSTRY ECOSYSTEM ANALYSIS
4.10.1 INTRODUCTION
4.10.2 ECOSYSTEM ARCHITECTURE — KEY ACTORS AND ROLES
4.10.2.1 CORE TECHNOLOGY PROVIDERS
4.10.2.2 ENABLING INSTITUTIONS
4.10.3 VALUE CHAIN AND FUNCTIONAL FLOWS
4.10.3.1 RESEARCH AND DISCOVERY
4.10.3.2 CLINICAL DEVELOPMENT AND REGULATORY VALIDATION
4.10.3.3 MANUFACTURING AND QUALITY ASSURANCE
4.10.3.4 DISTRIBUTION, PROCUREMENT AND CLINICAL ADOPTION
4.10.4 MARKET ENABLERS AND INFRASTRUCTURE
4.10.4.1 SCIENTIFIC AND REGULATORY ENABLERS
4.10.4.2 REIMBURSEMENT AND HEALTH-ECONOMICS INFRASTRUCTURE
4.10.4.3 MANUFACTURING AND SUPPLY-CHAIN CAPACITY
4.10.5 INTERDEPENDENCIES AND STRATEGIC PARTNERSHIPS
4.10.5.1 ACADEMIA-INDUSTRY TECHNOLOGY TRANSFER
4.10.5.2 VERTICAL INTEGRATION AND CONTRACT MANUFACTURING
4.10.5.3 CLINICAL NETWORKS AND KOL ECOSYSTEMS
4.10.6 RISKS, CONSTRAINTS AND SYSTEMIC VULNERABILITIES
4.10.6.1 REGULATORY COMPLEXITY FOR COMBINED PRODUCTS
4.10.6.2 SUPPLY-CHAIN CONCENTRATION AND MATERIAL RISK
4.10.6.3 EVIDENCE AND REIMBURSEMENT UNCERTAINTY
4.10.6.4 CLINICAL OPERATIONAL BARRIERS
4.10.7 STRATEGIC IMPLICATIONS AND RECOMMENDATIONS
4.10.8 OUTLOOK — EVOLUTION OF THE ECOSYSTEM
4.10.9 CONCLUSION
4.11 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.11.1 INTRODUCTION
4.11.2 RECENT TECHNOLOGICAL INNOVATIONS
4.11.2.1 ADVANCED PHOTOSENSITIZERS
4.11.2.2 OXYGEN-SELF-SUFFICIENT PLATFORMS
4.11.2.3 ALTERNATIVE ACTIVATION MODALITIES
4.11.2.4 SMART NANOPLATFORMS
4.11.2.5 NOVEL CHEMICAL STRUCTURES
4.11.3 STRATEGIC INNOVATIONS IN DELIVERY SYSTEMS
4.11.3.1 LIGHT DELIVERY DEVICES
4.11.3.2 COMBINATION THERAPIES
4.11.3.3 IMAGING INTEGRATION
4.11.4 KEY CHALLENGES
4.11.5 STRATEGIC THEMES
4.11.6 STRATEGIC IMPLICATIONS FOR MARKET PLAYERS
4.11.7 RECOMMENDATIONS
4.11.8 OUTLOOK AND STRATEGIC RISKS
4.11.9 CONCLUSION
4.12 PRICING ANALYSIS
4.12.1 INTRODUCTION
4.12.2 COMPONENTS OF THE TOTAL TREATMENT PRICE
4.12.2.1 PHOTOSENSITIZING AGENT (DRUG) COSTS
4.12.2.2 DEVICE CAPITAL AND MAINTENANCE COST
4.12.2.3 CONSUMABLES AND PROCEDURAL OVERHEAD
4.12.2.4 INDIRECT AND DOWNSTREAM COSTS
4.12.3 PRICING MODELS AND APPROACHES
4.12.3.1 COST-PLUS AND MARKUP MODELS
4.12.3.2 VALUE-BASED AND OUTCOMES-LINKED PRICING
4.12.3.3 BUNDLED PAYMENTS AND PROCEDURAL TARIFFS
4.12.3.4 SUBSCRIPTION AND MANAGED-SERVICE MODELS FOR DEVICES
4.12.4 REIMBURSEMENT LANDSCAPE
4.12.4.1 UNITED STATES: MEDICARE AND COMMERCIAL PAYERS
4.12.4.2 EUROPE AND OTHER HIGH-INCOME MARKETS
4.12.4.3 EMERGING MARKETS AND OUT-OF-POCKET DYNAMICS
4.12.5 REGIONAL PRICE DIFFERENTIALS AND DRIVERS
4.12.5.1 MANUFACTURING FOOTPRINT AND SUPPLY-CHAIN EFFECTS
4.12.5.2 REGULATORY BURDEN AND MARKET ACCESS TIMELINES
4.12.5.3 CLINICAL PRACTICE PATTERNS AND REIMBURSEMENT POLICY
4.12.6 PRICE SENSITIVITY, ACCESS, AND EQUITY
4.12.6.1 PRICE ELASTICITY IN HOSPITAL PROCUREMENT
4.12.6.2 PATIENT ACCESS AND SOCIOECONOMIC BARRIERS
4.12.7 COMPETITIVE & STRATEGIC PRICING IMPLICATIONS
4.12.7.1 DIFFERENTIATION-BASED PREMIUM PRICING
4.12.7.2 PENETRATION PRICING AND VOLUME STRATEGIES
4.12.7.3 MANAGED ENTRY AGREEMENTS AND OUTCOMES GUARANTEES
4.12.8 RECOMMENDATIONS FOR STAKEHOLDERS
4.12.8.1 FOR MANUFACTURERS
4.12.8.2 FOR PROVIDERS AND HOSPITAL SYSTEMS
4.12.8.3 FOR PAYERS AND POLICYMAKERS
4.12.9 RISKS, UNCERTAINTIES, AND FUTURE PRICE PRESSURES
4.12.10 CONCLUSION
5 TARIFFS & IMPACT ON THE MARKET
5.1 INTRODUCTION
5.2 TARIFF LANDSCAPE RELEVANT TO PDT PRODUCTS
5.2.1 CATEGORIES OF TRADE EXPOSURE
5.2.2 RECENT AND EMERGING TARIFF MEASURES OF CONSEQUENCE
5.3 DIRECT COST IMPACTS
5.3.1 INCREASED LANDED COSTS AND MARGIN COMPRESSION
5.3.2 PRICE VOLATILITY AND PROCUREMENT BUDGETING
5.4 SUPPLY-CHAIN & MANUFACTURING IMPLICATIONS
5.4.1 SUPPLIER DIVERSIFICATION AND RESHORING INCENTIVES
5.4.2 SOURCING OF HIGH-VALUE NANOMATERIALS AND COMPONENTS
5.4.3 REGULATORY AND QUALIFICATION COSTS FOR NEW SUPPLIERS
5.5 CLINICAL ACCESS, PRICING & REIMBURSEMENT EFFECTS
5.5.1 ACCESS RISK FOR PATIENTS AND PROVIDERS
5.5.2 REIMBURSEMENT PRESSURE AND HEALTH-ECONOMIC ASSESSMENTS
5.6 R&D, INNOVATION & COMPETITIVE IMPLICATIONS
5.6.1 DISRUPTION OF RESEARCH SUPPLIES AND COLLABORATION FLOWS
5.6.2 STRATEGIC REPOSITIONING AND COMPETITIVE ADVANTAGE
5.7 POLICY, COMPLIANCE & REGULATORY CONSIDERATIONS
5.7.1 USE OF WTO AND PREFERENTIAL TRADE RULES
5.7.2 TARIFF MITIGATION TOOLS AND ADVOCACY
5.8 RECOMMENDATIONS FOR STAKEHOLDERS
5.9 CONCLUSION
6 REGULATION COVERAGE
6.1 PRODUCT CODES
6.1.1 CERTIFIED STANDARDS
6.1.2 SAFETY STANDARDS
6.1.3 MATERIAL HANDLING & STORAGE
6.1.4 TRANSPORT & PRECAUTIONS
6.1.5 HAZARD IDENTIFICATION
6.1.6 CONCLUSION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CANCER
7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE THERAPIES
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN PHOTOSENSITIZERS AND DEVICES
7.1.4 EXPANDING RESEARCH AND CLINICAL DEVELOPMENT PIPELINE
7.2 RESTRAINTS
7.2.1 LIMITED DEPTH OF LIGHT PENETRATION
7.2.2 HIGH COST OF TREATMENT
7.3 OPPORTUNITIES
7.3.1 INTEGRATION WITH OTHER CANCER THERAPIES
7.3.2 DEVELOPMENT OF NOVEL PHOTOSENSITIZERS
7.3.3 M&A AND PARTNERSHIPS WITH ONCOLOGY DEVICE/LASER FIRMS AND PHARMA
7.4 CHALLENGES
7.4.1 TUMOR HYPOXIA AS A BIOLOGICAL BARRIER TO PHOTODYNAMIC THERAPY EFFICACY
7.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS
8 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 PHOTOSENSITIZER DRUGS
8.3 PHOTODYNAMIC THERAPY DEVICES
9 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION
9.1 OVERVIEW
9.2 SKIN & CUTANEOUS ONCOLOGY
9.3 HEAD & NECK
9.4 ESOPHAGAL
9.5 LUNG
9.6 BLADDER
9.7 CERVICAL
9.8 PROSTATE
10 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY
10.1 OVERVIEW
10.2 STANDALONE THERAPY
10.3 ADJUNCTIVE THERAPY
10.4 PALLIATION THERAPY
10.5 OTHERS
11 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE
11.1 OVERVIEW
11.2 EXTERNAL BEAM
11.3 INTRACAVITARY (ENDOSCOPIC) DELIVERY
11.4 INTERSTITIAL (INTERNAL) DELIVERY
11.5 OTHERS
12 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE
12.1 OVERVIEW
12.2 EARLY-STAGE CANCER
12.3 LATE-STAGE CANCER
13 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS
13.1 OVERVIEW
13.2 GERIATRIC
13.3 ADULTS
13.4 PEDIATRIC
14 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DERMATOLOGY & SKIN-CANCER CLINICS
14.4 AMBULATORY SURGICAL CENTERS (ASCS)
14.5 ACADEMIC & RESEARCH INSTITUTES
14.6 OTHERS
15 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 THIRD PARTY DISTRIBUTORS
15.4 ONLINE
15.5 OTHERS
16 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 NOVERTIS AG
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 GALDERMA S. A.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 PHOTOCURE
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 ADVANZ PHARMA CORP.
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENT
19.5 AMERISOURCE BERGEN CORPORATION
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 BIOFRONTERA AG
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 BIOLITEC HOLDING GMBH & CO KG
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 CARDINAL HEALTH
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 HEMERION THERAPEUTICS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 IMPACT BIOTECH
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 INOVA
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 LUMIBIRD
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 LUZITIN
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 MCKESSON
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MODULIGHT CORPORATION
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 ONCOLUX INC (FORMERLY LUMEDA INC.)
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SUN PHARMACEUTICAL INDUSTRIES LTD
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 THERALASE TECHNOLOGIES INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 3 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 4 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 5 NORTH AMERICA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 6 NORTH AMERICA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 NORTH AMERICA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 NORTH AMERICA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 10 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 13 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 16 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 17 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 19 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 22 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 24 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 25 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 28 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 31 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 32 NORTH AMERICA STANDALONE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 NORTH AMERICA ADJUNCTIVE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 NORTH AMERICA PALLIATION THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 NORTH AMERICA OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 37 NORTH AMERICA EXTERNAL BEAM IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 NORTH AMERICA INTRACAVITARY (ENDOSCOPIC) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA INTERSTITIAL (INTERNAL) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA EARLY-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 43 NORTH AMERICA LATE-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 45 NORTH AMERICA GERIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 NORTH AMERICA ADULTS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 NORTH AMERICA PEDIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH AMERICA DERMATOLOGY & SKIN-CANCER CLINICS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH AMERICA AMBULATORY SURGICAL CENTERS (ASCS) IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 54 NORTH AMERICA ACADEMIC & RESEARCH INSTITUTES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 55 NORTH AMERICA OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 56 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 NORTH AMERICA DIRECT TENDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 58 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 59 NORTH AMERICA ONLINE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 60 NORTH AMERICA OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 61 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 62 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 64 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 65 NORTH AMERICA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 NORTH AMERICA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 NORTH AMERICA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 69 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 71 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 73 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 75 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 77 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 79 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 80 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 81 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 83 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 84 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 85 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 86 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 87 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 88 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 90 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 91 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 U.S. PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 93 U.S. PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 94 U.S. PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 U.S. LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 U.S. ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 98 U.S. SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 U.S. SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 100 U.S. HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 U.S. HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 102 U.S. ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 U.S. ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 104 U.S. LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 U.S. LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 106 U.S. BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 U.S. BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 108 U.S. CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 U.S. CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 110 U.S. PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 U.S. PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 112 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 113 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 114 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 115 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 116 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 117 U.S. HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 U.S. HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 119 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 120 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 CANADA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 122 CANADA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 123 CANADA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 CANADA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 CANADA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 127 CANADA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 CANADA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 129 CANADA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 CANADA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 131 CANADA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 CANADA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 133 CANADA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 CANADA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 135 CANADA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 CANADA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 137 CANADA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 CANADA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 139 CANADA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 CANADA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 141 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 142 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 143 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 144 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 145 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 146 CANADA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 CANADA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 148 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 149 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 MEXICO PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 151 MEXICO PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 152 MEXICO PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 MEXICO LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 MEXICO ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 156 MEXICO SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 MEXICO SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 158 MEXICO HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 MEXICO HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 160 MEXICO ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 MEXICO ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 162 MEXICO LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 MEXICO LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 164 MEXICO BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 MEXICO BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 166 MEXICO CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 MEXICO CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 168 MEXICO PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 MEXICO PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 170 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 171 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 172 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 173 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 174 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 175 MEXICO HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 MEXICO HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 177 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: NORTH AMERICA VS REGIONAL ANALYSIS
FIGURE 5 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION
FIGURE 10 EXECUTIVE SUMMARY
FIGURE 11 STRATEGIC DECISIONS
FIGURE 12 TWO SEGMENTS COMPRISE THE NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE (2024)
FIGURE 13 INCREASING PREVALENCE OF CANCER ACROSS GLOBE EXPECTED TO DRIVE THE NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 PHOTOSENSITIZER DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET IN 2025 & 2032
FIGURE 15 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET-MARKET OVERVIEW
FIGURE 16 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024
FIGURE 17 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024
FIGURE 18 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032
FIGURE 19 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032
FIGURE 20 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024
FIGURE 21 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024
FIGURE 22 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032
FIGURE 23 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032
FIGURE 24 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024
FIGURE 25 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024
FIGURE 26 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032
FIGURE 27 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032
FIGURE 28 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024
FIGURE 29 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024
FIGURE 30 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032
FIGURE 31 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032
FIGURE 32 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024
FIGURE 33 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024
FIGURE 34 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032
FIGURE 35 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032
FIGURE 36 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2024
FIGURE 37 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032
FIGURE 38 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032
FIGURE 39 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032
FIGURE 40 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024
FIGURE 41 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024
FIGURE 42 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032
FIGURE 43 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032
FIGURE 44 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024
FIGURE 45 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024
FIGURE 46 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032
FIGURE 47 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032
FIGURE 48 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: SNAPSHOT (2024)
FIGURE 49 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY SHARE 2024 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
